Transthyretin Amyloidosis Treatment Market Key Players Analysis - American Express, Bank of America Corporation, Barclays PLC, Capital One, Citigroup Inc., JPMorgan Chase & Co.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Transthyretin Amyloidosis Treatment Market - (By Type (ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

According to the latest research by InsightAce Analytic, the Transthyretin Amyloidosis Treatment Market is valued at USD 5.5 Bn in 2024, and it is expected to reach USD 11.7 Bn by the year 2034, with a CAGR of 8.0% during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2890

Transthyretin amyloidosis (ATTR) treatment involves a range of therapeutic strategies designed to manage and slow the progression of this rare, progressive, and potentially fatal condition, which is caused by the accumulation of misfolded transthyretin proteins in various organs and tissues. Current treatment modalities primarily include pharmacological interventions aimed at stabilizing the transthyretin protein or inhibiting its production, along with supportive care measures to address symptoms and manage disease-related complications.

The global market for ATTR amyloidosis treatment is poised for substantial growth, driven by increased disease awareness and advancements in diagnostic capabilities for rare disorders. The condition's tendency to be underdiagnosed, particularly in patients with chronic health issues, presents a significant opportunity for earlier detection and timely intervention. As more advanced diagnostic technologies become accessible, the population eligible for treatment is expected to expand accordingly.

Additionally, growing investment in clinical research targeting new and emerging therapies for ATTR amyloidosis is further propelling market development. Public health initiatives led by government entities-focused on educating healthcare professionals and the general population-combined with improved reimbursement frameworks, are significantly enhancing treatment accessibility and accelerating the global adoption of innovative therapeutic options.

List of Prominent Players in the Transthyretin Amyloidosis Treatment Market:
• Acrotech Biopharma, LLC
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca PLC
• Astellas Pharma Inc.
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson
• Prothena Biosciences Limited
• Pfizer Inc.
• SOM Innovation Biotech, S.L.
• Abbvie, Inc.
• Sanofi
• Eidos Therapeutics, Inc
• BELLUS Health Inc

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Drivers:
The global transthyretin amyloidosis (ATTR) treatment market is experiencing notable growth, largely fueled by the expanding geriatric population, which is anticipated to increase by 16% and reach approximately 1.5 billion individuals in the coming years. This demographic shift is closely linked to a higher incidence of ATTR, particularly among older adults. According to Prothena, an estimated 400,000 individuals worldwide are affected by wild-type ATTR (ATTRwt) amyloidosis, while around 50,000 individuals have hereditary ATTR (hATTR) amyloidosis.

Research published by the National Center for Biotechnology Information (NCBI) indicates that ATTRwt is predominantly cardiac in nature and strongly associated with advanced age, underscoring aging as a critical risk factor. To address this, initiatives such as the Australian Amyloidosis Network's biennial traveling workshop have been instrumental in educating healthcare professionals and patients about the disease and its treatment options.

Challenges:
Despite growing awareness, several obstacles continue to hinder market growth. A key challenge is the insufficient level of awareness among healthcare providers, which can lead to misdiagnosis, delayed detection, and suboptimal treatment approaches. In addition, the high cost of recently approved therapies significantly limits broader patient access. For instance, Alnylam Pharmaceuticals reports an annual treatment cost of approximately USD 450,000 for Patisiran. Similarly, Inotersen, another approved therapeutic option, carries a comparable price point, creating affordability concerns and limiting market penetration.

Regional Trends:
North America is projected to maintain a dominant position in the ATTR treatment market, supported by improved diagnostic practices, increased prescription rates, and growing adoption of advanced therapies. The approval of ONPATTRO (Patisiran) by Health Canada for the treatment of hATTR polyneuropathy has played a pivotal role in driving regional growth. Concurrently, the Middle East and Africa are emerging as high-potential markets due to a combination of unmet medical needs, a rising prevalence of the disease, and an increasing number of drug approvals. These regions are expected to experience accelerated market expansion, aided by healthcare system improvements, heightened disease awareness, and a growing patient base.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2890

Segmentation of Transthyretin Amyloidosis Treatment Market-
By Type-
• ATTR-PN
• ATTR-CM
By Therapy-
• Targeted Therapy
o Onpattro
o Inotersen
o Vyndaqel/Vyndamax
• Supportive Therapy
• Pipeline Therapy
By Disease Type-
• Hereditary Transthyretin Amyloidosis
o Polyneuropathy
o Cardiomyopathy
o Mixed Type
• Wild Type Amyloidosis
By Distribution Channel-
• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/transthyretin-amyloidosis-treatment-market/2890

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.